[1]CurrentPatentAssignee:ASTRAZENECAPLC-US2008/4336,2008,A1Locationinpatent:Page/Pagecolumn21-22
[2]CurrentPatentAssignee:ASTRAZENECAPLC-US2008/4336,2008,A1Locationinpatent:Page/Pagecolumn19-20
[3]CurrentPatentAssignee:ASTRAZENECAPLC-US2008/234366,2008,A1Locationinpatent:Page/Pagecolumn14;15
[1]Patent:CN109400561,2019,A.Locationinpatent:Paragraph0083;0085-0087;0089-0091;0093-0095;0097;0098
[2]Patent:CN107540648,2018,A.Locationinpatent:Paragraph0041;0042;0054;0055
[3]Patent:CN107573311,2018,A.Locationinpatent:Paragraph0015;0022
[4]Patent:CN108084130,2019,B.Locationinpatent:Paragraph0050;0072-0074
[5]Patent:CN105481915,2016,A.Locationinpatent:Paragraph0023;0024
[6]Patent:US2008/4336,2008,A1.Locationinpatent:Page/Pagecolumn21-22
[7]Patent:WO2010/22313,2010,A2.Locationinpatent:Page/Pagecolumn35;38-39
[8]Patent:US2013/267694,2013,A1.Locationinpatent:Page/Pagecolumn0316
[9]Patent:WO2013/152476,2013,A1.Locationinpatent:Paragraph0260
[10]Patent:WO2013/152476,2013,A1
[11]Patent:US2017/29398,2017,A1.Locationinpatent:Paragraph0082-0083
[12]Patent:WO2017/221211,2017,A1.Locationinpatent:Page/Pagecolumn18
147-85-3
[1]Patent:WO2010/22313,2010,A2.Locationinpatent:Page/Pagecolumn35;38-39
[2]Patent:US2008/4336,2008,A1.Locationinpatent:Page/Pagecolumn23
[3]Patent:US2013/267694,2013,A1.Locationinpatent:Page/Pagecolumn0317;0318
[4]Patent:WO2013/152654,2013,A1.Locationinpatent:Paragraph0273
[1]Patent:US2008/4336,2008,A1.Locationinpatent:Page/Pagecolumn23-24
[2]Patent:WO2016/147197,2016,A1.Locationinpatent:Page/Pagecolumn18
[3]Patent:WO2017/42683,2017,A1.Locationinpatent:Page/Pagecolumn30
[1]Patent:US2008/4336,2008,A1.Locationinpatent:Page/Pagecolumn24
Title: SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Journal: Toxicology and applied pharmacology 20171015
Title: Pharmacological aspects of the safety of gliflozins.
Journal: Pharmacological research 20170401
Title: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Journal: Clinical pharmacokinetics 20150701
Title: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Journal: Clinical pharmacokinetics 20140101
Title: Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Journal: Diabetes, obesity & metabolism 20121101
Title: Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
Journal: Diabetes, obesity & metabolism 20121001
Title: Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20120913
Title: Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Journal: European journal of medicinal chemistry 20120901
Title: Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Journal: Diabetes 20120901
Title: Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Journal: Obesity (Silver Spring, Md.) 20120801
Title: Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Journal: Diabetes care 20120701
Title: C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry 20120701
Title: Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Journal: Postgraduate medicine 20120701
Title: A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Journal: Annals of medicine 20120601
Title: [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20120601
Title: [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Journal: Orvosi hetilap 20120506
Title: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Journal: International journal of clinical practice 20120501
Title: Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Journal: Expert opinion on therapeutic patents 20120501
Title: SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Journal: Journal of clinical pharmacology 20120401
Title: Dapagliflozin for the treatment of type 2 diabetes.
Journal: The Annals of pharmacotherapy 20120401
Title: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Journal: Annals of internal medicine 20120320
Title: Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study.
Journal: Annals of internal medicine 20120320
Title: Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
Journal: Annals of internal medicine 20120320
Title: Stereoselective C-glycosylation reactions with arylzinc reagents.
Journal: Organic letters 20120316
Title: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Journal: The Journal of clinical endocrinology and metabolism 20120301
Title: FDA rejects novel diabetes drug over safety fears.
Journal: Lancet (London, England) 20120211
Title: Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Journal: Advances in therapy 20120201
Title: Structural selectivity of human SGLT inhibitors.
Journal: American journal of physiology. Cell physiology 20120115
Title: Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20120101
Title: Facile synthesis of 1,2,3-triazole analogs of SGLT2 inhibitors by 'click chemistry'.
Journal: Bioorganic & medicinal chemistry letters 20120101
Title: Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Journal: PloS one 20120101
Title: Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Pharmacotherapy 20120101
Title: Red carpeting the newer antidiabetics.
Journal: Journal of pharmacology & pharmacotherapeutics 20120101
Title: The management of type 2 diabetic patients with hypoglycaemic agents.
Journal: ISRN endocrinology 20120101
Title: Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.
Journal: Core evidence 20120101
Title: Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Title: Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Title: Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.
Journal: BMJ open 20120101
Title: Drugs in traffic: the road to approval.
Journal: Nature medicine 20111206
Title: Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.
Journal: The AAPS journal 20111201
Title: The role of visfatin in diabetic nephropathy.
Journal: Chonnam medical journal 20111201
Title: Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Journal: Clinical therapeutics 20111101
Title: Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Journal: Expert review of clinical pharmacology 20111101
Title: Dapagliflozin--redefining treatment of T2DM?
Journal: Nature reviews. Endocrinology 20111011
Title: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Journal: Diabetes, obesity & metabolism 20111001
Title: Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Journal: Bioorganic & medicinal chemistry 20111001
Title: Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Journal: Bioorganic & medicinal chemistry 20110915
Title: Kidney in diabetes: from organ damage target to therapeutic target.
Journal: Current drug metabolism 20110901
Title: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Journal: Diabetes care 20110901
Title: Challenges for the treatment of diabetes mellitus.
Journal: Recent patents on endocrine, metabolic & immune drug discovery 20110901
Title: Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
Title: Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
Title: [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
Journal: Revue medicale suisse 20110831
Title: Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
Journal: Diabetes, obesity & metabolism 20110801
Title: Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Journal: European journal of medicinal chemistry 20110701
Title: A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Journal: Postgraduate medicine 20110701
Title: Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20110615
Title: Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20110615
Title: New diabetes drugs go beyond insulin to flush out excess sugar.
Journal: Nature medicine 20110601
Title: Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
Journal: Journal of medicinal chemistry 20110428
Title: Discovery of non-glucoside SGLT2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20110415
Title: Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Journal: Diabetes, obesity & metabolism 20110401
Title: Learning from glycosuria.
Journal: Diabetes 20110301
Title: SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Journal: Diabetes 20110301
Title: Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
Journal: Kidney international. Supplement 20110301
Title: A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Journal: Discovery medicine 20110301
Title: Type 2 diabetes: uses of thiazolidinediones and insulin.
Journal: Diabetes care 20110201
Title: Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.
Journal: Bioorganic & medicinal chemistry letters 20110115
Title: Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Journal: Journal of medicinal chemistry 20110113
Title: Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Journal: Diabetes, obesity & metabolism 20110101
Title: Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics.
Journal: Current topics in medicinal chemistry 20110101
Title: Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.
Journal: Indian journal of nephrology 20110101
Title: Management of diabetes across the course of disease: minimizing obesity-associated complications.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Title: SGLT-2 inhibitors in development for type 2 diabetes treatment.
Journal: The review of diabetic studies : RDS 20110101
Title: Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20101201
Title: Dapagliflozin: more than just another oral glucose-lowering agent?
Journal: Expert opinion on investigational drugs 20101201
Title: Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma.
Journal: Bioanalysis 20101201
Title: [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
Journal: Sheng li ke xue jin zhan [Progress in physiology] 20101201
Title: Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201
Title: Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201
Title: A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.
Journal: North American journal of medical sciences 20101201
Title: The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
Journal: Diabetes, obesity & metabolism 20101101
Title: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Journal: Diabetes care 20101001
Title: Diabetes: Dapagliflozin: an insulin-independent, therapeutic option for type 2 diabetes mellitus.
Journal: Nature reviews. Endocrinology 20101001
Title: Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Journal: Current opinion in nephrology and hypertension 20100901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100901
Title: Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.
Journal: Bioorganic & medicinal chemistry 20100815
Title: (5-Bromo-2-methyl-phen-yl)(4-eth-oxy-phen-yl)methanone.
Journal: Acta crystallographica. Section E, Structure reports online 20100801
Title: Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Journal: Lancet (London, England) 20100626
Title: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England) 20100626
Title: ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Journal: Bioorganic & medicinal chemistry 20100615
Title: Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.
Journal: Bioorganic & medicinal chemistry letters 20100601
Title: Neuropathy, retinopathy, and glucose-lowering treatments.
Journal: Diabetes care 20100601
Title: Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Journal: Diabetes, obesity & metabolism 20100601
Title: Dapagliflozin: BMS 512148; BMS-512148.
Journal: Drugs in R&D 20100501
Title: (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Journal: Journal of medicinal chemistry 20100422
Title: Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
Journal: Bioorganic & medicinal chemistry 20100315
Title: Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Journal: Drugs 20100305
Title: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100301
Title: C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.
Journal: Bioorganic & medicinal chemistry letters 20100301
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100101
Title: [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Journal: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101
Title: Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20091215
Title: Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: IDrugs : the investigational drugs journal 20091201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20091201
Title: (5-Bromo-2-chloro-phen-yl)(4-ethoxy-phen-yl)methanone.
Journal: Acta crystallographica. Section E, Structure reports online 20091201
Title: Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20091022
Title: O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20091001
Title: Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Journal: Expert opinion on pharmacotherapy 20091001
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20091001
Title: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
Journal: Diabetes care 20090901
Title: Dapagliflozin for the treatment of type 2 diabetes.
Journal: The Annals of pharmacotherapy 20090701
Title: Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Journal: Kidney international 20090601
Title: Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Journal: Clinical pharmacology and therapeutics 20090501
Title: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Journal: Clinical pharmacology and therapeutics 20090501
Title: Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Journal: Journal of medicinal chemistry 20090409
Title: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Journal: Diabetes care 20090401
Title: Dapagliflozin: an emerging treatment option in type 2 diabetes.
Journal: Expert opinion on investigational drugs 20090301
Title: Diabetes treatment.
Journal: Diabetes care 20090301
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090301
Title: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Journal: Diabetes, obesity & metabolism 20090201
Title: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901
Title: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Journal: International journal of clinical practice 20080801
Title: Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Journal: Diabetes 20080601
Title: Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20080313
Title: Molecule of the month. Dapagliflozin.
Journal: Drug news & perspectives 20071201
